ABSTRACT
There still have been limited data regarding COVID-19 in lung transplant recipients (LTR). We sought the outcomes after COVID-19 infection in LTR using our largest dataset. We analyzed our database of LTR who were diagnosed with COVID-19 between March 26, 2020 and September 6, 2022. First, we investigated the clinical outcomes of the all cohort, and then divided them into three groups depending on their time of diagnosis (Dx, 1st wave: 03/2020-10/2020, 2nd: 11/2020-11/2021, and 3rd: 12/2021-09/2022), and compared these results. 210 LTR (median age, 67;67% male) were enrolled. The median time from LT to their Dx was 2.1 years. Five patients had the Dx during their index admission for LT whereas all of them died during their admission. One hundred forty patients (67%) required readmission, including 46 (33%) receiving ICU management. Among those hospitalized, 35 patients (25%) were intubated and 7 patients (5%) were placed on VV ECMO. Overall survival was 67% at 1 year and 59% at 2 years post-Dx (Figure 1). While 89 patients (42%) were unvaccinated at the time of their Dx, 121 patients (58%) were vaccinated including 63 patients (30%) with boosters. Although survival was significantly better in the 3rd period (Figure 1), hospital mortality has not changed (1st: 28%, 2nd: 38%, 3rd: 28%). Vaccination was the only significant predictor for hospital admission (initial series vs none: odds ratio [OR] 0.22;boosters vs none: OR 0.27). Age ≥ 70 years (OR 2.87) and initial series of vaccines (vs None: OR 3.10;vs boosters: OR 3.71) contribute to hospital mortality as an independent predictor. Survival post-COVID-19 infection in LTR continues to improve, however, hospital mortality remains remarkably high with 30%. Whereas vaccination appears to have been impactful in preventing hospital admission, vaccination also has demonstrated inconsistent results for reducing hospital mortality. Further research is continued focused on how to better identify the high risk LTR who may lead to the mortality. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
In December 2019, novel coronavirus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within a few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID-19 vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID-19 infection or at least diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno-compromised patients should not receive live vaccines as they can cause vaccine-related disease and hence the guidelines suggest that all transplant recipients should receive age-appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population.
ABSTRACT
In December 2019 Novel corona virus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID 19 Vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID -19 infection or atleast diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno compromised patients should not receive live vaccines as they can cause vaccine related disease and hence the guidelines suggest that all transplant recipients should receive age appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population. © 2021 Indian Journal of Transplantation ;Published by Wolters Kluwer - Medknow.